Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection

Carla Zoja,1 Daniela Corna,1 Elena Gagliardini,1 Sara Conti,1 Lorenzo Arnaboldi,2 Ariela Benigni,1 and Giuseppe Remuzzi1,3

1Mario Negri Institute for Pharmacological Research, Centro Anna Maria Astori, Science and Technology Park Kilometro Rosso, Bergamo; 2Department of Pharmacological Sciences, Università di Milano, Milan; and 3Unit of Nephrology and Dialysis, Azienda Ospedaliera, Ospedali Riuniti di Bergamo, Bergamo, Italy

Submitted 25 January 2010; accepted in final form 12 August 2010

Zoja C, Corna D, Gagliardini E, Conti S, Arnaboldi L, Benigni A, Remuzzi G. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. Am J Physiol Renal Physiol 299:F1203–F1211, 2010. First published August 18, 2010; doi:10.1152/ajprenal.00045.2010.—The capacity of renin-angiotensin system (RAS) inhibitors to delay progression of diabetic nephropathy depends on the time at which therapy is started. A multimodal intervention is required to afford renoprotection in overt diabetic nephropathy. Here we assessed the effects of maximal RAS inhibition by angiotensin-converting enzyme (ACE) inhibitor plus angiotensin II type 1 receptor blocker (ARB) in combination with statin in rats with overt diabetic nephropathy. Uninephrectomized rats made diabetic by streptozotocin were orally treated from 4 (when proteinuria and renal lesions had developed) to 8 mo with vehicle, lisinopril plus candesartan, lisinopril plus candesartan plus rosuvastatin, or rosuvastatin alone. Systolic blood pressure increased in diabetic rats and was significantly lowered by combined therapies. Dual RAS blockade significantly reduced proteinuria compared with vehicle. Addition of statin further lowered proteinuria to control levels. Glomerulosclerosis was ameliorated by RAS inhibitors or statin, and regression was achieved by the addition of statin. Loss of podocytes of diabetic rats was limited by ACE inhibitor plus ARB while normalized by the three drugs. Defective nephrin expression of diabetes was increased by dual RAS blockade or statin and restored by the triple therapy. Tubular damage, interstitial inflammation, and expression of the fibrotic markers transforming growth factor (TGF)-β1 and phosphorylated Smad 2/3 in tubuli were significantly reduced by the triple regimen. These data suggest a strategy to target proteinuria to try to achieve regression of renal disease in diabetic patients who do not fully benefit from RAS inhibition alone.

Dual renin-angiotensin system blockade; rosuvastatin; streptozotocin-induced diabetes; glomerulosclerosis; tubular inflammation and fibrosis

DIABETES MELLITUS IS EMERGING as a global health care problem with devastating human, social, and economic impact, such that the total number of people with diabetes is projected to rise from 171 million in 2000 to 366 million in 2030 (54). About one-third of diabetic patients develop diabetic nephropathy, which accounts for >40% of new cases of end-stage renal disease (38). Diabetic nephropathy is associated with a dramatic excess of cardiovascular morbidity, and cardiovascular mortality is the primary cause of early death in diabetic patients (30). In proteinuric chronic nephropathies, inhibitors of the renin-angiotensin system (RAS) are effective in reducing proteinuria and slowing renal disease progression owing to their actions on systemic and glomerular hypertension as well as to their unique property of ameliorating size selectivity of the glomerular barrier, thereby limiting excess protein ultrafiltration and its deleterious consequences (1, 37). The capacity of RAS inhibitors to delay progression of diabetic nephropathy, however, crucially depends on the time at which therapy is started. Thus, in rats with streptozotocin-induced diabetes, early administration of angiotensin-converting enzyme (ACE) inhibitor significantly reduced systemic blood pressure and normalized urinary protein excretion. By contrast, a late intervention was unable to limit proteinuria despite an effective control of blood pressure (31). Results of clinical trials have shown that ACE inhibitors prevent the progression to overt nephropathy in the early microalbuminuric phase of diabetes (24, 33), whereas in a more advanced phase ACE inhibitor or angiotensin II type 1 receptor blockers (ARB) provide imperfect protection (8, 20, 41). A more complex strategy than single pharmacological intervention in the RAS may therefore be required to afford renoprotection in diabetic patients with overt nephropathy. The combination of an ACE inhibitor and an ARB has been suggested as a way to maximize RAS blockade by affecting both the bioavailability and the activity of angiotensin II (32, 56). Metanalysis of randomized trials in patients with or without diabetes indicated that proteinuria reduction is greater when ACE inhibitor and ARB are used together (18), suggesting that a more efficient amelioration of the glomerular barrier can be obtained by the combined therapy (32), which might translate into increased renoprotection (42). Recently, the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) (23) in patients with atherosclerotic vascular disease or diabetes with end-organ damage reported that although combination therapy reduced albuminuria to a greater extent than monotherapy, it worsened major renal outcomes. This study, however, had several weak points—as recently highlighted (43)—and the conclusions on dual RAS blockade are far from robust.

Statins or 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors have pleiotropic properties that complement their cholesterol-lowering effects. In addition to inhibiting the rate-limiting step in cholesterol biosynthesis, namely, the conversion of HMG CoA into mevalonate, statins interfere with prenylation of Ras and Rho family small GTP-binding proteins, thereby blocking the activation of signaling pathways and transcription factors, which regulate inflammatory and fibrogenic genes critical to renal disease progression (25).

A multimodal intervention strategy using all available tools to target urinary proteins has been envisioned as a rational
approach to maximizing renoprotection in patients with chronic renal disease (44). Experimental data support this notion (57). Indeed, in rats with severe passive Heymann nephritis that only partially responded to ACE inhibitor therapy, the addition of statin to a chronic background of ACE inhibition and ARB induced remission of proteinuria and conferred complete protection of the kidney (57).

In the present study we wanted 1) to establish whether renoprotection can be better achieved by a multidrug approach with ACE inhibitor and ARB combined with statin than by dual RAS blockade in a setting of severe diabetic nephropathy and 2) to understand the mechanisms underlying the beneficial effects afforded by the triple therapy by looking at its impact in maintaining glomerular and tubulointerstitial structure and function.

MATERIALS AND METHODS

Animals and Experimental Design

Male Sprague-Dawley rats (Charles River Italia, Calco, Italy) with initial body weights of 270–330 g were used. Animal care and treatment were conducted in accordance with institutional guidelines that are in compliance with national (Decreto Legislativo n.116, Gazzetta Ufficiale suppl 40, 18 febbraio 1992, Circolare n.8, Gazzetta Ufficiale 14 luglio 1994) and international (EEC Council Directive 86/609, OJL358-1, December 1987; Guide for the Care and Use of Laboratory Animals, U.S. National Research Council, 1996) laws and policies. Animal protocols were submitted to and approved by the Institutional Animal Care and Use Committee (IACUC) of “Mario Negri” Institute, Milan, Italy. All animals were housed in a room in which the temperature was kept constant on a 12:12-h dark-light cycle and allowed free access to standard diet containing 20% protein by weight and tap water. Animals were subjected to right nephrectomy and allowed free access to standard diet containing 20% protein by weight and tap water. Animals were subjected to right nephrectomy 7 days before the induction of diabetes to hasten the development of the disease (3). Diabetes was induced by a single intravenous injection of streptozotocin (60 mg/kg body wt; Sigma, St. Louis, MO). The presence of diabetes was confirmed 2 days later by the presence of sugar in the urine. Diabetic rats received daily evening injections of insulin (Ultratard HM, A. Menarini Diagnostics, Florence, Italy). Diabetes was induced by a single intravenous injection of streptozotocin (60 mg/kg body wt; Sigma, St. Louis, MO). The presence of diabetes was confirmed 2 days later by the presence of sugar in the urine. Diabetic rats received daily evening injections of insulin (Ultratard HM, A. Menarini Diagnostics, Florence, Italy). Diabetic rats received daily evening injections of insulin (Ultratard HM, A. Menarini Diagnostics, Florence, Italy). Diabetic rats received daily evening injections of insulin (Ultratard HM, A. Menarini Diagnostics, Florence, Italy). Diabetes was induced by a single intravenous injection of streptozotocin (60 mg/kg body wt; Sigma, St. Louis, MO). The presence of diabetes was confirmed 2 days later by the presence of sugar in the urine. Diabetic rats received daily evening injections of insulin (Ultratard HM, A. Menarini Diagnostics, Florence, Italy).

Estimation of Glomerular Volume and Podocyte Count

Glomerular volume was calculated with the use of a computer-based image analysis system (Image J 1.42q, http://rsb.info.nih.gov/ij) as previously described (22). Podocytes were identified with an antibody directed against Wilms tumor 1 (WT1), a podocyte-specific marker. The estimation of the average number of podocytes per glomerulus was determined in 30 glomeruli for each animal by morphometric analysis as proposed by Weibel (51) on digital images acquired by fluorescence microscopy (Olympus IX70) as previously reported (21).

Immunohistochemical Analysis

Indirect immunofluorescence was performed for the detection of interstitial macrophage infiltration (14) and adipophilin staining. Alkaline phosphatase-fast red technique was used to evaluate transforming growth factor (TGF)-β1 expression (35). Immunoperoxidase method (2) was employed for nephrin and phosphorylated (p)Smad 1/5/8 detection. The following primary antibodies were used: mouse anti-ED1 antigen present in rat monocytes/macrophages (1:100, Chemicon International, Temecula, CA), rabbit anti-TGF-β1 [1:100, Santa Cruz Biotechnology, Santa Cruz, CA], goat anti-nephrin (1:100, Santa Cruz), goat anti-pSmad 2/3 (1:50, Santa Cruz), and mouse anti-adipophilin (1:50, Progen Biotech, Heidelberg, Germany). ED1-positive cells were counted in 15 randomly selected high-power microscopic fields (×400) on average per animal. Adipophilin staining was evaluated in 13 randomly selected microscopic fields (×200) on average per animal, and the percentage of area occupied by adipophilin-positive signal was quantified by setting a “threshold” with Image J’s thresholding tool (1.42q, http://rsb.info.nih.gov/ij). Intensity of tubular TGF-β1 and pSmad 2/3 and glomerular nephrin signals were graded on a scale of 0 to 3 (0, no staining; 1, weak staining; 2, staining of moderate intensity; 3, strong staining) in 20 randomly selected tubulointerstitial microscopic fields (×200) or 30 glomeruli on average per animal. Negative controls were obtained by omitting the primary antibody on adjacent sections.

Lipid Extraction and Free Cholesterol and Cholesteryl Ester Analysis

Kidneys were thawed and homogenized with chloroform-methanol (2:1), BHT 0.01%, and KCl 0.05% plus a known amount of stigmastanol and cholesterol heptadecanoate (synthesized by Prof. Ermanno Valoti’s laboratory, Università degli Studi di Milano, Milan, Italy) as internal standards. Two extractions were performed after 3-h shakings at 4°C and the organic phase was dried under nitrogen and resuspended in chloroform-methanol (2:1) plus BHT. The aqueous phase was dried, and the resulting pellet was dissolved in 0.1 N NaOH. Total protein amount was measured and results are expressed as micrograms of lipid per milligram of protein (40).
An aliquot of the lipid extract was loaded onto prerun and activated channeled Silica TLC plates (BioMap) in hexane-diethyl ether-acetic acid (80:20:1 vol/vol/vol). After the run, the plates were sprayed with dichlorofluorescein (0.15% in ethanol) and the spots corresponding to those of known standards of free and esterified cholesterol were scraped off. Free cholesterol was extracted from silica with hexane-isopropanol and detected without derivatization. Cholesteryl esters were derivatized with methanol-HCl 3 N-toluene for 2 h at 75°C. The analysis was performed on a DANI 1000 gas liquid chromatographer (GLC) (DANI Instruments, Milan, Italy) equipped with a flame ionization detector and a 30-m, 0.32-mm, 0.25-μm MEGA-1 (Mega Columns, Legnano, Italy) fused silica column. The flow of hydrogen was at a constant pressure of 1 bar, and the detector temperature was 300°C. Oven temperature ranged for free cholesterol from 185 to 300°C (total run 15 min) and for cholesteryl esters from 160 to 300°C (total run 28 min). Chromatograms were recorded and the area of each peak quantified by Clarity Software (Clarity, Prague, Czech Republic). The mass of free cholesterol was calculated by comparing its area with that of the internal standard (stigmasterol), while the mass of cholesteryl esters was evaluated after integrating and summing the areas of each fatty acid composing the ester and comparing the total area with that of the internal standard (cholesteryl heptadecanoate) (49).

Statistical Analysis

Results are expressed as means ± SE. Data were analyzed by ANOVA with the Bonferroni post hoc analysis for multiple comparison or nonparametric Kruskal-Wallis test. The statistical significance level was defined as \( P < 0.05 \).

RESULTS

Systemic Parameter

By the end of the study one rat died in each group of diabetic rats. All control rats were alive. Diabetic rats gained weight with time, although to a lesser extent than control rats (Table 1). At the end of the study, mean body weights of rats given a combination of lisinopril and candesartan or lisinopril plus candesartan plus rosvastatin were significantly lower (\( P < 0.05 \)) than those of diabetic rats treated with vehicle or statin alone. Food intake was comparable among diabetic rats and significantly higher than that of control rats (Table 1).

As shown in Table 1, serum cholesterol levels were comparable among the groups of diabetic and control rats. Serum triglyceride levels were significantly increased in diabetic rats given vehicle compared with control rats. Hypertriglyceridemia was reduced in all diabetic treated rats, as a likely consequence of the antiproteinuric effect of the therapy, although statistical significance was not achieved.

Rats with diabetes showed over time a significant increase in SBP compared with control rats (Fig. 1). Treatment with ACE inhibitor plus ARB, or with the addition of rosvastatin, maintained SBP at values significantly lower than those of the vehicle group and even of age-matched control rats. In rats given rosvastatin alone, SBP values were numerically lower than those measured in vehicle-treated rats, which is in line with the antihypertensive effects reported for statins (13, 27) and attributed to drug interaction with endothelial function or angiotensin II receptors (7).

Renal Parameters

The time course of urinary protein excretion is shown in Fig. 2A. At 4 mo, rats with diabetes exhibited significantly higher values of urinary protein excretion than control rats and were randomized to receive treatments. Proteinuria progressively increased in rats given vehicle, averaging 94 ± 24 mg/day at 8 mo. Combined administration of lisinopril and candesartan reduced proteinuria compared with pretreatment, and levels were significantly (\( P < 0.05 \)) lower than those measured in vehicle-treated rats (month 8, 38 ± 12 mg/day). Remarkably, when rosvastatin was added on top of dual RAS blockade, proteinuria was further lowered and normalized (month 8, 24 ± 2 mg/day; \( P < 0.01 \) vs. vehicle) to the levels of control rats (month 8, 25 ± 3 mg/day). In diabetic rats treated with rosvastatin the mean proteinuria levels were numerically lower than those measured in rats receiving vehicle (month 8, 78 ± 20 mg/day). A similar trend was observed for urinary albumin excretion (Fig. 2B).

Table 1. Systemic parameters measured in diabetic rats at 8 mo after disease induction

<table>
<thead>
<tr>
<th>Groups</th>
<th>Body Wt, g</th>
<th>Food Intake, g/24 h</th>
<th>Serum Cholesterol, mg/dl</th>
<th>Serum Triglycerides, mg/dl</th>
<th>Creatinine Clearance, ml·min⁻¹·100 g⁻¹</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vehicle</td>
<td>472 ± 15†</td>
<td>41 ± 2†</td>
<td>110 ± 9</td>
<td>195 ± 30*</td>
<td>0.26 ± 0.03</td>
</tr>
<tr>
<td>Lisinopril + candesartan</td>
<td>422 ± 6†‡§</td>
<td>43 ± 3*</td>
<td>102 ± 2</td>
<td>126 ± 18</td>
<td>0.30 ± 0.02</td>
</tr>
<tr>
<td>Lisinopril + candesartan + rosvastatin</td>
<td>417 ± 14†‡§</td>
<td>40 ± 4*</td>
<td>106 ± 3</td>
<td>124 ± 15</td>
<td>0.27 ± 0.02</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>483 ± 32*</td>
<td>39 ± 3*</td>
<td>102 ± 2</td>
<td>147 ± 15</td>
<td>0.25 ± 0.01</td>
</tr>
<tr>
<td>Control</td>
<td>607 ± 21</td>
<td>24 ± 2</td>
<td>100 ± 0</td>
<td>112 ± 8</td>
<td>0.29 ± 0.01</td>
</tr>
</tbody>
</table>

Values are expressed as means ± SE. *\( P < 0.05 \); †\( P < 0.01 \) vs. control rats; ‡\( P < 0.05 \) vs. vehicle; §\( P < 0.05 \) vs. rosvastatin.

Fig. 1. Time course of systolic blood pressure in control and diabetic rats given a combination of lisinopril and candesartan, lisinopril + candesartan + rosvastatin, or rosvastatin, from 4 to 8 mo. Data are means ± SE. *\( P < 0.05 \), **\( P < 0.01 \) vs. control; †\( P < 0.01 \) vs. vehicle; ‡\( P < 0.05 \), ##\( P < 0.01 \) vs. rosvastatin at corresponding time.
Renal function, as evaluated by creatinine clearance at month 8, was mildly impaired in diabetic rats given vehicle compared with control rats (Table 1). Treatments did not significantly affect renal function.

**Glomerular Pathology**

**Histology.** Morphological evaluation of the kidney in diabetic rats at 4 mo revealed the presence of 2 ± 0.01% sclerotic glomeruli on average (P < 0.05 vs. age-matched control rats: 0.08 ± 0.002%) (Fig. 3). At 8 mo diabetic rats given vehicle showed variable degrees of glomerulosclerosis and hyalinosis with segmental collapse of the glomerular tuft affecting 10.6 ± 1.8% of glomeruli on average (P < 0.01 vs. diabetes at 4 mo; P < 0.01 vs. age-matched control rats: 2.2 ± 0.4%). Administration of lisinopril plus candesartan decreased the incidence of glomerulosclerosis (4.9 ± 1.6%), but not to a significant extent. A complete protection was instead conferred by the addition of rosuvastatin to the RAS inhibitors, so that the percentage of glomeruli with sclerotic changes (1.2 ± 0.3%) was lower than that observed in diabetic animals at 4 mo, thereby suggesting regression of glomerular lesions. Rosuvastatin treatment limited the degree of glomerulosclerosis (5.7 ± 1.6%), but without reaching a statistical significance compared with vehicle.

**Morphometric analysis: glomerular volume, podocyte number, and nephrin expression.** Glomerular hypertrophy was observed in diabetic rats receiving vehicle (Fig. 4A). Treatments with lisinopril plus candesartan decreased the incidence of either lisinopril plus candesartan or rosuvastatin alone numerically reduced the glomerular volume. A significant reduction (P < 0.05) of glomerular hypertrophy was achieved after the triple therapy. The number of podocytes per glomerulus was significantly decreased in diabetic rats given vehicle compared with control rats (P < 0.05). Loss of podocytes per glomerulus was limited by dual RAS blockade. Treatment with the triple therapy restored the number of podocytes to control values (Fig. 4A). Only a partial effect on podocyte number was observed after treatment with rosuvastatin alone. An intense expression of nephrin protein with the typical epithelial-like staining pattern was detected in glomeruli of control rats (score: 2.70 ± 0.08, Fig. 4Be). Diabetic rats given vehicle showed a significant (P < 0.01) reduction in nephrin expression (score: 1.49 ± 0.19, Fig. 4Ba) compared with control rats. Nephrin staining was markedly increased after the administration of either lisinopril plus candesartan (score: 2.23 ± 0.13, P < 0.05 vs. vehicle; Fig. 4Bc) or rosuvastatin alone (score: 2.22 ± 0.22, P < 0.05 vs. vehicle; Fig. 4Bd). Notably, in diabetic animals receiving the triple therapy nephrin expression was restored, so that levels were similar to those of control animals (score: 2.68 ± 0.06, P < 0.01 vs. vehicle; Fig. 4Bd).

**Tubulointerstitial Pathology**

**Histology.** In diabetic rats glomerular injury was associated with mild tubular damage (Fig. 5A), which increased with time from 4 mo (score: 0.60 ± 0.24) to 8 mo (score: 1.01 ± 0.03, P < 0.01 vs. controls: 0.16 ± 0.12). Tubular lesions were significantly reduced by combined treatment of lisinopril and candesartan (score: 0.25 ± 0.25, P < 0.05 vs. vehicle) and normalized by the triple therapy (score: 0.13 ± 0.13, P < 0.01 vs. vehicle at 8 mo; # P < 0.05 vs. vehicle; Fig. 4Bd).
vs. vehicle). In diabetic rats given rosuvastatin the score of tubular damage averaged 0.60 ± 0.24.

**Interstitial inflammation and fibrosis.** Accumulation of ED1-positive monocytes/macrophages was found in peritubular cortical interstitium of diabetic rats given vehicle (Fig. 5B). Treatment with lisinopril plus candesartan numerically reduced the interstitial accumulation of inflammatory cells compared with vehicle. A further significant reduction was observed after the triple therapy. Rosuvastatin alone limited inflammatory cell infiltrates to an extent similar to the combined treatment of ACE inhibitor and ARB. Tubular lesions and interstitial inflammation observed in diabetic animals given vehicle were accompanied by increased tubular expression of the profibrotic marker TGF-β1 (Fig. 6). TGF-β1 staining was decreased after ACE inhibitor plus ARB treatment (Fig. 6C) compared with vehicle-treated rats (Fig. 6A). A further reduction was observed after the triple regimen (Fig. 6D), to the extent that TGF-β1 expression was fairly comparable to that found in control rats (Fig. 6E). A 24% reduction in tubular TGF-β1 expression compared with vehicle was observed after treatment with rosuvastatin alone (Fig. 6B). Upregulation of tubular TGF-β1 in diabetic rats given vehicle was associated with activation of the intracellular cascade of Smad proteins, particularly pSmad 2/3 (6), which are specifically involved in the regulation of
TGF-β-dependent fibrogenic responses (Fig. 7). The increased pSmad 2/3 staining in tubuli of diabetic rats on vehicle (Fig. 7A) was partially, but not significantly, reduced by lisinopril plus candesartan (Fig. 7C). A statistically significant difference was achieved after the addition of rosuvastatin to the dual therapy (Fig. 7D). Rosuvastatin alone (Fig. 7B) limited tubular pSmad 2/3 expression to an extent similar to that of the dual therapy.

**DISCUSSION**

Results from the present study demonstrate that in rats with overt diabetic nephropathy that benefited only partially from ACE inhibitor treatment (3, 14), the addition of candesartan to

---

**Fig. 6.** Scores (top) and representative photomicrographs (bottom) of tubular transforming growth factor (TGF)-β1 expression in diabetic rats receiving vehicle (A), rosuvastatin (B), lisinopril + candesartan (C), or lisinopril + candesartan + rosuvastatin (D) and in control rats (E). Staining was completely abrogated by omitting the primary antibody on the adjacent section on each slide, indicating staining specificity (F). Original magnification × 200. Score values are expressed as means ± SE. **P < 0.01 vs. control; °P < 0.05, °°P < 0.01 vs. rosuvastatin.

---

**Fig. 5.** Tubular damage (A) and interstitial accumulation of ED1-positive monocytes/macrophages (B) in diabetic rats after administration of vehicle, rosuvastatin, lisinopril + candesartan, or lisinopril + candesartan + rosuvastatin and in control rats. Values are expressed as means ± SE. *P < 0.05, **P < 0.01 vs. control; °P < 0.05, °°P < 0.01 vs. vehicle. HPF, high-power field.

---

**Fig. 4.** Scores (top) and representative photomicrographs (bottom) of tubular transforming growth factor (TGF)-β1 expression in diabetic rats receiving vehicle (A), rosuvastatin (B), lisinopril + candesartan (C), or lisinopril + candesartan + rosuvastatin (D) and in control rats (E). Staining was completely abrogated by omitting the primary antibody on the adjacent section on each slide, indicating staining specificity (F). Original magnification × 200. Score values are expressed as means ± SE. **P < 0.01 vs. control; °P < 0.05, °°P < 0.01 vs. rosuvastatin.

---

**Fig. 3.** Tubular damage (A) and interstitial accumulation of ED1-positive monocytes/macrophages (B) in diabetic rats after administration of vehicle, rosuvastatin, lisinopril + candesartan, or lisinopril + candesartan + rosuvastatin and in control rats. Values are expressed as means ± SE. *P < 0.05, **P < 0.01 vs. control; °P < 0.05, °°P < 0.01 vs. vehicle. HPF, high-power field.

---

**Fig. 2.** Tubular damage (A) and interstitial accumulation of ED1-positive monocytes/macrophages (B) in diabetic rats after administration of vehicle, rosuvastatin, lisinopril + candesartan, or lisinopril + candesartan + rosuvastatin and in control rats. Values are expressed as means ± SE. *P < 0.05, **P < 0.01 vs. control; °P < 0.05, °°P < 0.01 vs. vehicle. HPF, high-power field.

---

**Fig. 1.** Tubular damage (A) and interstitial accumulation of ED1-positive monocytes/macrophages (B) in diabetic rats after administration of vehicle, rosuvastatin, lisinopril + candesartan, or lisinopril + candesartan + rosuvastatin and in control rats. Values are expressed as means ± SE. *P < 0.05, **P < 0.01 vs. control; °P < 0.05, °°P < 0.01 vs. vehicle. HPF, high-power field.

---

**Fig. 5.** Tubular damage (A) and interstitial accumulation of ED1-positive monocytes/macrophages (B) in diabetic rats after administration of vehicle, rosuvastatin, lisinopril + candesartan, or lisinopril + candesartan + rosuvastatin and in control rats. Values are expressed as means ± SE. *P < 0.05, **P < 0.01 vs. control; °P < 0.05, °°P < 0.01 vs. vehicle. HPF, high-power field.

---

**Fig. 4.** Tubular damage (A) and interstitial accumulation of ED1-positive monocytes/macrophages (B) in diabetic rats after administration of vehicle, rosuvastatin, lisinopril + candesartan, or lisinopril + candesartan + rosuvastatin and in control rats. Values are expressed as means ± SE. *P < 0.05, **P < 0.01 vs. control; °P < 0.05, °°P < 0.01 vs. vehicle. HPF, high-power field.

---

**Fig. 3.** Tubular damage (A) and interstitial accumulation of ED1-positive monocytes/macrophages (B) in diabetic rats after administration of vehicle, rosuvastatin, lisinopril + candesartan, or lisinopril + candesartan + rosuvastatin and in control rats. Values are expressed as means ± SE. *P < 0.05, **P < 0.01 vs. control; °P < 0.05, °°P < 0.01 vs. vehicle. HPF, high-power field.

---

**Fig. 2.** Tubular damage (A) and interstitial accumulation of ED1-positive monocytes/macrophages (B) in diabetic rats after administration of vehicle, rosuvastatin, lisinopril + candesartan, or lisinopril + candesartan + rosuvastatin and in control rats. Values are expressed as means ± SE. *P < 0.05, **P < 0.01 vs. control; °P < 0.05, °°P < 0.01 vs. vehicle. HPF, high-power field.

---

**Fig. 1.** Tubular damage (A) and interstitial accumulation of ED1-positive monocytes/macrophages (B) in diabetic rats after administration of vehicle, rosuvastatin, lisinopril + candesartan, or lisinopril + candesartan + rosuvastatin and in control rats. Values are expressed as means ± SE. *P < 0.05, **P < 0.01 vs. control; °P < 0.05, °°P < 0.01 vs. vehicle. HPF, high-power field.

---

**Renal Lipid Accumulation**

Lipid analysis revealed a numerically increased free and esterified cholesterol content in the kidneys of diabetic rats receiving vehicle (Table 2). A trend toward a decrease in cholesterol was observed in the kidneys of rats treated with rosuvastatin, alone or in association with the other regimens, although statistical significance was not reached. Treatment with lisinopril plus candesartan showed only a modest effect in reducing lipid accumulation, confined to the esterified form of cholesterol (Table 2).

The immunolocalization of adipocyte differentiation-related protein adipophilin, a marker of cytoplasmic lipid droplets (16), revealed almost no lipid droplets in control rats and a significant increase of the typical lipid droplets as ring-shaped red dots in the tubules of diabetic rats on vehicle (Table 2). The accumulation of lipid droplets was significantly reduced by combined treatment with lisinopril and candesartan and by the triple therapy. Rosuvastatin alone also reduced tubular adipophilin expression to a significant extent (Table 2).
could be related to the combined drugs’ action on glomerular filtration barrier function. Abnormalities in size-selective function of the glomerular capillary wall have been consistently shown by dextran or Ficoll fractional clearance studies in experimental and human diabetes, with increase in the number of large nonselective pores responsible for the passage of circulating macromolecules in the urinary space (14, 29, 36, 39, 41). Both ACE inhibitors and ARB reduced pore dimensions and improved size selectivity of the glomerular membrane in rats with streptozotocin-induced diabetes (14, 36) and in patients with type 1 diabetes (29) which translated into a reduction of proteinuria. That statins may ameliorate diabetes-induced changes in glomerular permeability has been suggested by recent data showing that treatment with rosuvastatin resulted in near-normalization of the abnormal glomerular filtration of 70- and 40-kDa dextrans in streptozotocin-diabetic rats (28). The favorable effects of rosuvastatin on glomerular permeability were possibly related to statin’s ability to inhibit the activation of Rho signaling pathways shown to decrease endothelial barrier function (10).

Podocytes span the glomerular capillaries and function via the slit diaphragm as a critical barrier to macromolecule filtration (46). Studies have highlighted that reduction in podocyte number is an early feature of diabetic nephropathy that predicts long-term urinary albumin excretion and progressive course of the disease (12, 26, 53). Reduced podocyte number can reflect increased podocyte detachment and/or apoptosis (48, 55). As a consequence of podocyte depletion, the remaining podocytes are induced to cover the denuded basement membrane, whereas the mesangial compartment expands to further compensate for the ongoing cell loss (46), which would favor glomerular hypertrophy in diabetes. In the present study we confirmed a reduced podocyte number per glomerulus in diabetic rats given vehicle, which was associated with increased glomerular volume and the development of glomerulosclerosis.

The dual blockade of RAS with lisinopril and candesartan markedly limited podocyte loss, but only triple therapy resulted in a complete preservation of podocyte number and a reduction of glomerular volume. That RAS inhibitors can influence podocyte loss has been previously documented in diabetic rats (14, 15). An interesting finding here is that the administration of rosuvastatin alone partially limited podocyte loss (14, 15). An interesting finding here is that the administration of rosuvastatin alone partially limited podocyte loss, but only triple therapy resulted in a complete preservation of podocyte number and a reduction of glomerular volume. That RAS inhibitors can influence podocyte loss has been previously documented in diabetic rats (14, 15). Among possible mechanisms, recent in vitro data have shown that rosuvastatin protected injured podocytes from undergoing apoptosis through upregulation of the cell cycle

Table 2. Free and esterified cholesterol levels and adipophilin expression in kidney tissue of diabetic rats at 8 mo after disease induction

<table>
<thead>
<tr>
<th>Groups</th>
<th>Free Cholesterol, µg/mg protein</th>
<th>Esterified Cholesterol, µg/mg protein</th>
<th>Adipophilin Expression, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vehicle</td>
<td>65.04 ± 2.42</td>
<td>4.20 ± 0.53</td>
<td>1.80 ± 0.1*</td>
</tr>
<tr>
<td>Lisinopril + candesartan</td>
<td>66.20 ± 3.53</td>
<td>3.36 ± 0.23</td>
<td>0.50 ± 0.3†</td>
</tr>
<tr>
<td>Rosuvastatin</td>
<td>54.46 ± 4.23</td>
<td>3.21 ± 0.40</td>
<td>0.51 ± 0.5†</td>
</tr>
<tr>
<td>Control</td>
<td>58.18 ± 2.39</td>
<td>3.24 ± 0.12</td>
<td>0.72 ± 0.3†</td>
</tr>
<tr>
<td></td>
<td>62.31 ± 4.90</td>
<td>3.40 ± 0.82</td>
<td>0.27 ± 0.5</td>
</tr>
</tbody>
</table>

Values are expressed as means ± SE. *P < 0.05 vs. control rats; †P < 0.01 vs. vehicle.
regulator p21, a prosurvival player in podocyte apoptosis (11). There is also evidence showing that statins may directly stimulate Akt-dependent survival pathway in podocytes. Thus treatment with statins reduced oxidized LDL-induced apoptosis in cultured human podocytes by activating Akt/phosphatidylinositol 3-kinase signaling pathway (9). In the same study, it was shown that the statin-induced Akt activation also protected podocytes from the loss of nephrin, the slit diaphragm protein that acts to maintain slit pore integrity and renal filtration capacity (50), which would provide a mechanism for the antiproteinuric effect of statins. In the present study, the defective nephrin protein levels found in the glomeruli of diabetic rats receiving vehicle were improved by rosuvastatin to an extent similar to that of dual RAS blockade. While improvement in nephrin expression after ACE inhibitor treatment has been previously documented in both experimental (5, 14, 17) and human (19) diabetic nephropathy, few reports are available showing the ability of statins to ameliorate decreased expression of nephrin, and they refer to models of proteinuric renal disease other than diabetic nephropathy (47, 52). Remarkably, when rosuvastatin was added to lisinopril and can-desartan, we obtained restoration of nephrin expression, which paralleled the regression of proteinuria to normal values.

In the present study, we unequivocally showed that normalization of proteinuria by the triple therapy translated into preservation of the tubular structure, reduction of interstitial inflammation, and almost complete abrogation of the abnormal tubular expression of TGF-β1, a central player in the fibrogenic process of diabetic nephropathy (34, 45). Moreover, the finding of reduced staining for pSmad 2/3 in the tubuli of rats treated with ACE inhibitor plus ARB plus statin further indicated the antifibrotic effects of the triple regimen. It has been reported that in the profibrotic process TGF-β signaling involves TGF-β receptor-activated Smad 2 and 3, which, once phosphorylated, bind to Smad 4. The resulting Smad complex translocates into the nucleus, where it cooperates with numerous transcription factors to regulate the transcription of profibrogenic genes (6).

In conclusion, these data indicate that adding a statin to a background of ACE inhibition and angiotensin II receptor blocker blockade therapy normalizes proteinuria and affords better renoprotection than a dual RAS blockade in rats with overt diabetic nephropathy. These results reinforce the concept that targeting proteinuria is the best way to induce regression of renal disease, and suggest this multidrug approach as a strategy for both proteinuric diabetic and nondiabetic patients who do not fully benefit from ACE inhibitor and ARB treatment.

ACKNOWLEDGMENTS

The authors thank Giovanna Barcella and Romana Stacchetti for their precious help in animal care and Monica Locatelli for excellent technical assistance. Manuela Passera helped to prepare the manuscript.

GRANTS

The present study was supported in part by a grant from AstraZeneca Italia, Milan, Italy. S. Conti was the recipient of a fellowship from Fondazione Aiuti per la Ricerca sulle Malattie Rare (ARMR) in memory of Lidia D’Arcangelo, Bergamo, Italy.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

REFERENCES


